Search

SVV-001

SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in … SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.

PX-478

PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

Amperozide

It inhibits dopamine release and alters the firing of dopaminergic neurons. … Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication

ISIS 325568

It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.

Muvalaplin

Muvalaplin has a monoisotopic molecular weight of 710.4 Da. … Muvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events).

ABT-510

It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

Thiram

Thiram may be used in dermatology as a scabicide [T436]. … Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].

ALS-08

ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

Otamixaban

It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

EVT-101